The two companies licensed to cultivate and sell marijuana – LeafLine Labs and Minnesota Medical Solutions (MinnMed) – will benefit immensely from Wednesday’s decision to add intractable pain to the state’s list of qualifying medical conditions. LeafLine Labs and MinnMed can now breathe a huge sigh of relief about the future – and potentially capture millions of additional dollars in sales annually.
“This is going to do wondrous things for the program,” said Kyle Kingsley, the CEO of MinnMed. “We’ve had so many patients that don’t currently qualify that obviously benefit from cannabis, and for them to have a solution on the horizon, it’s a huge relief for our team.”
Read more at Marijuana Business Daily
Written by John Schroyer